Skip to main content
Premium Trial:

Request an Annual Quote

ChromaDex, Scripps Reach Deal to Generate Tandem Mass Spec Data for Metabolite Database

NEW YORK (GenomeWeb News) – Natural products firm ChromaDex and the Scripps Center for Metabolomics have formed a partnership to generate tandem mass spectrometry data for compounds for inclusion in a metabolite database

Data from compounds from ChromaDex's products and phytochemical catalog will be included in the Scripps Metlin Metabolite Database, which contains metabolite information, such as tandem mass spectrometry information, for more than 55,000 potentially therapeutic compounds.

Metlin, however, has only limited data on natural products, and including such information would enable researchers to screen potential compounds for use in areas of clinical interest, such as cancer, heart disease, diabetes, and Alzheimer's disease, ChromaDex said.

The collaboration announced today "will further advance small molecule profiling to increase demand for natural product libraries through the ease of the Internet to assist in finding candidate compounds for research and development," ChromaDex Founder and Chief Scientific Officer Frank Jaksch said in a statement.

ChromaDex is based in Irvine, Calif., and provides solutions and ingredients to the dietary supplement, food and beverage, cosmetic, and pharmaceutical industries.

Gary Siuzdak, senior director for the Center for Metabolomics and Mass Spectrometry Scripps Research Institute, added that the inclusion of ChromaDex compounds "will expand Metlin's compound library and mass spectrometry data to nutraceuticals and many novel plant-related natural products. The importance in the ChromaDex/Metlin partnership is that it will facilitate metabolomics experiments around the world."

Financial and other terms of the deal were not disclosed.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.